Business Wire

MA-GRANDSTREAM-NETWORKS

23.2.2021 09:32:07 CET | Business Wire | Press release

Share
Video, Portable and Carrier-Grade IP Phones from Grandstream Now Available for ISTRA by Enreach UCaaS Platform

Enreach, the fast-growing European unified communications group, has announced that multiple IP phones from Grandstream have been certified for use on its Unified Communications as a Service (UCaaS) platform, ISTRA by Enreach. Through Enreach for Service Providers , partners and their customers have immediate access to portable and video phones from Grandstream, plus carrier-grade devices designed for mass-deployment.

Bertrand Pourcelot, Managing Director at Enreach for Service Providers, said: “Grandstream’s name has become synonymous with IP phones that combine superior quality and ease-of-use, with options to suit a wide variety of budgets and requirements. Grandstream is a good fit for our portfolio of supporting products for the ISTRA by Enreach UCaaS platform, which is already used by approximately one million users via over 100 service providers in 20-plus countries.”

Grandstream IP phones certified for ISTRA by Enreach

Highlights of the ISTRA-certified range include Grandstream’s GXV3300 series of advanced IP video phones for Android, bringing multimedia AV communications to the desktop, with tablet-style functionality and web access.

For greater mobility in the workplace, the cordless WP810 and WP820 are portable WiFi IP phones, providing robust design and comprehensive features. As well as office or home-working environments, these phones are ideal for retail, logistics, medical, security and other vertical markets where portability is a benefit.

When large volumes of handsets are needed, the GRP2600 series of Carrier-Grade IP phones deliver powerful performance, simplicity of use and easy deployment. As well as supporting basic communications, these devices include next generation features for high-end users.

About ISTRA by Enreach

The ISTRA cloud based UCaaS platform is already deployed by over 100 service providers in more than 20 countries with approximately one million users. It is also the foundation for Enreach’s future-facing platform strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader.

Enreach for Service Providers

Based in Sophia-Antipolis, France, Enreach for Service Providers (previously known as Centile Telecom Applications) is a European leader in the development of Cloud PBX and unified communications platforms for operators and integrators. As well as supporting Enreach for Service Providers own service provider customers, ISTRA by Enreach UCaaS platform is the foundation for Enreach’s future-facing strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader. https://enreach.com/en/for-service-providers

About Enreach

Enreach is the parent company of various labels such as Voiceworks, Swyx, Eazit, i4IP, ipnordic, M Mobility, HeroBase, Network Telecom, Botsquad and masvoz. Enreach provides collaboration technology and telecoms services via their reselling and service providing partners or direct brands that are transformative for SMEs and the people that work with them. All brands contribute to intelligent, integrated IT and communication solutions that ensure optimal communication and workflow between organisations. Enreach’s mission is to give businesses access to the best communication and collaboration tools with an easy, user-centric interface built around their specific needs and systems. The group’s products put powerful features in reach of every business, no matter the industry or size, so their employees can focus on getting amazing things done. Enreach is active in the core markets Germany, the Netherlands, Denmark, UK, Spain and France with activities in 25 countries and 950 employees. https://enreach.com/

About Grandstream

Grandstream Networks, Inc. has been connecting the world since 2002 with SIP Unified Communications products and solutions that allow businesses to be more productive than ever before. Our award-winning solutions serve the small and medium business and enterprises markets and have been recognized throughout the world for their quality, reliability and innovation. Grandstream solutions lower communication costs increase security protection and enhance productivity. Their open standard SIP-based products offer broad interoperability throughout the industry, along with unrivaled features and flexibility. Visit www.grandstream.com for more information or connect with us on Facebook , LinkedIn and Twitter .

Link:

ClickThru

Social Media:

https://www.facebook.com/grandstreamnetworksinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye